Eli Lilly Expands Obesity Drug Pipeline Amid Record Highs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: CNBC
- Drug Development Progress: Eli Lilly unveiled data on its next-generation obesity drug retatrutide at the American Diabetes Association conference, showing a 19% weight loss at a 4 mg dose, comparable to the highest dose of its blockbuster Zepbound, indicating the company's leading position in the obesity drug market.
- Strong Market Performance: Shares of Eli Lilly have risen approximately 35% year-to-date, while rival Novo Nordisk's stock has declined by about 18%, reflecting increased investor confidence in Lilly's obesity drug pipeline and the potential for further market share expansion.
- Drug Potential Analysis: Goldman Sachs noted that Lilly's obesity pipeline highlights a “rapidly evolving next-gen innovation engine,” while Barclays stated that retatrutide presents significant commercial opportunities that could reshape the obesity pharmacotherapy landscape.
- Long-term Health Benefits: Jim Cramer emphasized the long-term health benefits of GLP-1 drugs, arguing that employers and insurers limiting coverage are making a mistake, as these drugs could lead to significant improvements in various health issues, including cardiovascular diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 43.920
Low
42.00
Averages
54.67
High
70.00
Current: 43.920
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Weight Loss Drug Market Prospects
- Market Growth Potential: Analysts project rapid growth in the weight loss market over the coming years, with Eli Lilly and Novo Nordisk as industry leaders, showing a stark contrast in performance with Eli Lilly's 40% stock increase and Novo Nordisk's 42% decline over the past year, highlighting intense market competition.
- Eli Lilly's Advantages: Eli Lilly's weight loss drug Zepbound is currently the best-seller in this niche, with Q1 revenue soaring 56% year-over-year to $19.8 billion and EPS skyrocketing 170% to $8.26, underscoring its strong market position in chronic weight management.
- Novo Nordisk's Catch-Up: Novo Nordisk's oral GLP-1 drug Wegovy has achieved over two million prescriptions in Q1, and while facing competitive pressure from Eli Lilly, the approval of a high-dose Wegovy formulation could enhance its competitive edge.
- Investment Value Comparison: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly's dominance in the weight loss sector and diversified portfolio make it a more compelling investment choice at this time.
See More
Eli Lilly and Novo Nordisk Compete in Weight Loss Market
- Market Leadership: Eli Lilly leads the weight loss market with a remarkable 56% year-over-year revenue increase to $19.8 billion in Q1, while its EPS soared 170% to $8.26, showcasing its strong performance in chronic weight management and solidifying its market share.
- Product Line Expansion: Eli Lilly's weight loss drug Zepbound has become the best-seller in this niche, and the newly approved oral GLP-1 therapy Foundayo is attracting patients hesitant about injectable drugs, which is expected to expand its addressable market and enhance its customer base.
- Changing Competitive Dynamics: Novo Nordisk is regaining competitiveness in the weight loss market, with its oral Wegovy achieving over two million prescriptions since launch, and the newly approved high-dose Wegovy is likely to enhance its market share, helping it compete with Eli Lilly's Zepbound.
- Future Potential: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly is still viewed as the more valuable investment due to its diversified product portfolio and dominant position in the weight loss sector.
See More
Markets Pause as Investors Assess Latest Rally Amid Fed Meeting
- Market Rally Assessment: Markets are taking a breather as investors reassess the recent rally driven by easing tensions in the Middle East, particularly ahead of the Federal Reserve's first policy meeting under Chair Kevin Warsh, where interest rates are expected to remain steady, reflecting cautious sentiment regarding future policy directions.
- SpaceX Stock Frenzy: SpaceX shares crossed a $2.5 trillion valuation on Monday, although Wall Street analysts are raising concerns about high valuations, especially as veteran short-seller Jim Chanos warns that investors rarely profit from buying companies valued at more than 100 times revenue, which may impact retail investor confidence.
- Novo Nordisk's China Plans: Novo Nordisk announced plans to seek regulatory approval for its oral Wegovy weight-loss pill in China within the next few months, aiming to challenge Eli Lilly's market position, indicating its strategic intent to expand in the Chinese market.
- Economic Data Focus: Investors are closely tracking the upcoming release of the U.S. ADP weekly employment change and housing starts data, which will provide further directional guidance for the market, especially in the context of the Federal Reserve's policy decisions.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
Markets Pause as Investors Assess Latest Rally Amid Fed Meeting
- Market Rally Assessment: Markets took a breather as investors evaluated the recent rally driven by easing tensions in the Middle East, showing caution ahead of the Federal Reserve's first policy decision under Chair Kevin Warsh regarding interest rates.
- SpaceX Options Trading Launch: With SpaceX stock crossing a $2.5 trillion valuation, retail investors are gearing up for options trading, speculating on a potential volatility-driven 'gamma squeeze', although analysts express concerns about high valuations.
- Novo Nordisk's China Plans: Novo Nordisk plans to seek regulatory approval for its oral Wegovy weight-loss pill in China within the next few months, aiming to challenge Eli Lilly's market position and indicating its intent to expand in the Chinese market.
- Economic Data Focus: Investors are closely tracking the upcoming release of U.S. ADP employment change and housing starts data, which will provide crucial indicators of economic health and could influence future investment decisions.
See More
Analysis of Three Promising Biotech Companies
- Madrigal Pharmaceuticals Breakthrough: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first medicine for metabolic dysfunction-associated steatohepatitis, with over 42,250 patients treated and a 127% year-over-year revenue increase to $311.3 million in Q1, indicating strong market demand and growth potential.
- Axsome Therapeutics Progress: Axsome Therapeutics' Auvelity achieved $153.2 million in sales in Q1, a 59% increase year-over-year, and received label expansion for treating Alzheimer's disease agitation, with projected peak sales of $8 billion, showcasing its robust growth potential in mental health.
- Kailera Risks and Opportunities: Kailera Therapeutics focuses on developing weight loss medications and, despite having no marketed products, its leading candidate ribupatide is in phase 3 trials, potentially positioning it in the rapidly growing anti-obesity market, appealing to risk-tolerant investors.
- Market Competition and Challenges: While Madrigal and Axsome excel in their respective fields, they face competition from large pharmaceutical companies like Novo Nordisk, and Kailera's lack of marketed products increases investment risk, necessitating careful evaluation of potential clinical and regulatory challenges.
See More
Analysis of Weight Loss Drug Market Prospects
- Market Growth Potential: Analysts project rapid growth in the weight loss market over the coming years, with Eli Lilly and Novo Nordisk as industry leaders, showing a stark contrast in performance with Eli Lilly's 40% stock increase and Novo Nordisk's 42% decline over the past year, highlighting intense market competition.
- Eli Lilly's Advantages: Eli Lilly's weight loss drug Zepbound is currently the best-seller in this niche, with Q1 revenue soaring 56% year-over-year to $19.8 billion and EPS skyrocketing 170% to $8.26, underscoring its strong market position in chronic weight management.
- Novo Nordisk's Catch-Up: Novo Nordisk's oral GLP-1 drug Wegovy has achieved over two million prescriptions in Q1, and while facing competitive pressure from Eli Lilly, the approval of a high-dose Wegovy formulation could enhance its competitive edge.
- Investment Value Comparison: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly's dominance in the weight loss sector and diversified portfolio make it a more compelling investment choice at this time.
See More
Eli Lilly and Novo Nordisk Compete in Weight Loss Market
- Market Leadership: Eli Lilly leads the weight loss market with a remarkable 56% year-over-year revenue increase to $19.8 billion in Q1, while its EPS soared 170% to $8.26, showcasing its strong performance in chronic weight management and solidifying its market share.
- Product Line Expansion: Eli Lilly's weight loss drug Zepbound has become the best-seller in this niche, and the newly approved oral GLP-1 therapy Foundayo is attracting patients hesitant about injectable drugs, which is expected to expand its addressable market and enhance its customer base.
- Changing Competitive Dynamics: Novo Nordisk is regaining competitiveness in the weight loss market, with its oral Wegovy achieving over two million prescriptions since launch, and the newly approved high-dose Wegovy is likely to enhance its market share, helping it compete with Eli Lilly's Zepbound.
- Future Potential: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly is still viewed as the more valuable investment due to its diversified product portfolio and dominant position in the weight loss sector.
See More
Markets Pause as Investors Assess Latest Rally Amid Fed Meeting
- Market Rally Assessment: Markets are taking a breather as investors reassess the recent rally driven by easing tensions in the Middle East, particularly ahead of the Federal Reserve's first policy meeting under Chair Kevin Warsh, where interest rates are expected to remain steady, reflecting cautious sentiment regarding future policy directions.
- SpaceX Stock Frenzy: SpaceX shares crossed a $2.5 trillion valuation on Monday, although Wall Street analysts are raising concerns about high valuations, especially as veteran short-seller Jim Chanos warns that investors rarely profit from buying companies valued at more than 100 times revenue, which may impact retail investor confidence.
- Novo Nordisk's China Plans: Novo Nordisk announced plans to seek regulatory approval for its oral Wegovy weight-loss pill in China within the next few months, aiming to challenge Eli Lilly's market position, indicating its strategic intent to expand in the Chinese market.
- Economic Data Focus: Investors are closely tracking the upcoming release of the U.S. ADP weekly employment change and housing starts data, which will provide further directional guidance for the market, especially in the context of the Federal Reserve's policy decisions.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
Markets Pause as Investors Assess Latest Rally Amid Fed Meeting
- Market Rally Assessment: Markets took a breather as investors evaluated the recent rally driven by easing tensions in the Middle East, showing caution ahead of the Federal Reserve's first policy decision under Chair Kevin Warsh regarding interest rates.
- SpaceX Options Trading Launch: With SpaceX stock crossing a $2.5 trillion valuation, retail investors are gearing up for options trading, speculating on a potential volatility-driven 'gamma squeeze', although analysts express concerns about high valuations.
- Novo Nordisk's China Plans: Novo Nordisk plans to seek regulatory approval for its oral Wegovy weight-loss pill in China within the next few months, aiming to challenge Eli Lilly's market position and indicating its intent to expand in the Chinese market.
- Economic Data Focus: Investors are closely tracking the upcoming release of U.S. ADP employment change and housing starts data, which will provide crucial indicators of economic health and could influence future investment decisions.
See More
Analysis of Three Promising Biotech Companies
- Madrigal Pharmaceuticals Breakthrough: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first medicine for metabolic dysfunction-associated steatohepatitis, with over 42,250 patients treated and a 127% year-over-year revenue increase to $311.3 million in Q1, indicating strong market demand and growth potential.
- Axsome Therapeutics Progress: Axsome Therapeutics' Auvelity achieved $153.2 million in sales in Q1, a 59% increase year-over-year, and received label expansion for treating Alzheimer's disease agitation, with projected peak sales of $8 billion, showcasing its robust growth potential in mental health.
- Kailera Risks and Opportunities: Kailera Therapeutics focuses on developing weight loss medications and, despite having no marketed products, its leading candidate ribupatide is in phase 3 trials, potentially positioning it in the rapidly growing anti-obesity market, appealing to risk-tolerant investors.
- Market Competition and Challenges: While Madrigal and Axsome excel in their respective fields, they face competition from large pharmaceutical companies like Novo Nordisk, and Kailera's lack of marketed products increases investment risk, necessitating careful evaluation of potential clinical and regulatory challenges.
See More
